Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02694328 · ClinicalTrials.gov registry record · Phase 3
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
A Phase 3 study of Schizophrenia, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 561
- Enrollment target
- 20
- Study locations
NCT02694328: Completed Phase 3 study of Schizophrenia, sponsored by Alkermes.
NCT02694328 is a Phase 3 study of Schizophrenia that has completed, run by Alkermes. The registered enrollment target is 561 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (159% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02694328, a Phase 3 study of Schizophrenia, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 561 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
Conditions Studied
Interventions
- DRUG Olanzapine
- DRUG ALKS 3831
Study Locations (20)
California
- Alkermes Investigational Site - Anaheim
- Alkermes Investigational Site - Cerritos
- Alkermes Investigational Site - Culver City
- Alkermes Investigational Site - Garden Grove
- Alkermes Investigational Site - Glendale
- Alkermes Investigational Site - Long Beach
- Alkermes Investigational Site - National City
- Alkermes Investigational Site - Oakland
- Alkermes Investigational Site - Oceanside
- Alkermes Investigational Site - Orange
- Alkermes Investigational Site - Pico Rivera
- Alkermes Investigational Site - Redlands
- Alkermes Investigational Site - San Diego
- Alkermes Investigational Site - San Diego
- Alkermes Investigational Site - Temecula
- Alkermes Investigational Site - Torrance
Arkansas
- Alkermes Investigational Site - Little Rock
- Alkermes Investigational Site - Springdale
District of Columbia
- Alkermes Investigational Site - Washington D.C.
Florida
- Alkermes Investigational Site - Lauderhill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 561 participants |
| Start Date | 2016-03-02 |
| Est. Completion | 2018-11-07 |
| Phase | Phase 3 |
What the finished NCT02694328 record still lists
NCT02694328 is an interventional study that assigns participants to a tested intervention. The registered 561 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (159% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Olanzapine is the first listed.
NCT02694328 names 20 study sites across 4 states, led by California, Arkansas, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02694328 about?
NCT02694328 is a clinical study titled "A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)". This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
What is the current status of trial NCT02694328?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 561 participants. The study started on 2016-03-02. Estimated completion is 2018-11-07.
What conditions does trial NCT02694328 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02694328?
The interventions under investigation include: Olanzapine (DRUG), ALKS 3831 (DRUG).
Who is sponsoring clinical trial NCT02694328?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02694328 being conducted?
This trial has 20 study locations across Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02694328's enrollment target sits among peer trials
561 34th of 315 higher than 282 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07007065 · 561 participants · Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI